By Sally Pipes
“Nonetheless, critics have denounced remdesivir’s price tag. Some have pointed to an earlier ICER assessment, which said Gilead could recoup its costs by selling remdesivir for just $1 per dose. Public Citizen, a progressive advocacy group, claims that price is justified because the federal government invested $70 million in remdesivir’s development, largely by funding early-stage research and clinical trials. As such, it claims taxpayers have already paid for the drug.”
Read the full article here.